tradingkey.logo

Merck Says Keytruda Plus Paclitaxel Improved Overall Survival In Patients With Ovarian Cancer

ReutersFeb 27, 2026 3:24 PM

- Merck & Co Inc MRK.N:

  • KEYTRUDA® (PEMBROLIZUMAB) PLUS PACLITAXEL WITH OR WITHOUT BEVACIZUMAB SIGNIFICANTLY IMPROVED KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL (OS) VERSUS PACLITAXEL WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI